



Breadcrumb

1. [Home](#)

Entity Print



Mette Hazenberg
EBMT Treasurer
Netherlands

In 2024, income of EBMT continued to grow. For the second year in a row, revenue generated through post-authorisation safety (PAS) studies and pharmaceutical industry-initiated and/or partnered projects represented the largest source of income. Other sources of income are the Annual Meeting, corporate sponsorships, accreditation fees, grants, and investment income.

Missing from this list for the first time are the membership fees. Historically, reporting centres paid membership fees, with benefits such as discounts on

registration fees for the Annual Meeting and on JACIE accreditation fees in return. However, it became clear that the membership fee model was no longer representative of the reciprocal nature of the relationship between reporting centres and EBMT. The Board of Association therefore decided to abolish centre membership fees as of 2024, in line with the 2023–2026 Strategic Plan. In addition, several structural investments have been implemented, also in accordance with the Strategic Plan:

The Registry

The most urgent priority in recent years has been to replace the outdated IT structure of the Registry. This new Registry, built under the dedicated supervision of the Clinical Research and Registry Department and the Registry Committee, was launched in August 2023. Costs for the development and implementation of the new Registry have been covered through the EuroTraCTOR grant and earmarked reserves, to which EUR 2.0M was appropriated from the net result of 2023. In 2024, EUR 1.2M of the earmarked Registry reserves was used for further development, including the analytical tool, completion of the core database, mapping and migration of MedB data, and the development of study modules for collecting study and MedC data. In total, the costs for the Registry's development have amounted to EUR 4.1M (EUR 0.6M from EuroTraCTOR).

(Almost) All in One EBMT Cloud

Another important structural investment has been the reorganisation of EBMT's IT infrastructure. Until recently, EBMT offices had separate IT systems, hosted by the hospitals where EBMT had offices. In 2024, the Barcelona and Leiden EBMT offices migrated to the EBMT cloud, which also hosts the Registry, and the Paris office is expected to follow in 2025.

JACIE Inspectors' Per Diem

To support the further development of EBMT's Quality of Care programme and, in particular, the role of JACIE Inspectors, it was decided to increase the per diem allowance for inspectors.

Working Parties

Since the introduction of the Working Party budgets in 2013, the WP budget structure has been further refined. The Science Fund was created in 2021, and in 2022 it was decided that WPs would share in the results of studies with pharmaceutical companies and events. Most recently, in 2023, the fixed budget was raised from EUR 16K to EUR 26K, and from then onwards the variable budget has been provided in EUR instead of FTE. This means that unspent budget can now be kept in reserve, which was not possible when the budget was allocated in FTE.

In 2024, a WP Budget Task Force was established to conduct an in-depth evaluation of the scientific and educational indicators that determine each WP's variable budget. The goal of this review is to redefine budget distribution to foster new scientific and educational output. The Harmonisation Workshops, initiated in 2023 to create guidelines and clinical recommendations with dedicated funding, continued in 2024 and were equally successful.

Investing in Structure to Secure Our Mission

Over the past 10 years, the EBMT workforce has steadily grown to a total of 133.1 FTE, with 125.6 FTE on an EBMT contract and 7.5 FTE hired from third parties. In 2024, several new roles were added, including an Annual Meeting Manager, an Educational Content Coordinator, an IT Project Manager, a Legal Support & Data Privacy Coordinator, a Quality Assurance Coordinator, and a Financial Accountant. No further expansion of the workforce is anticipated for the coming year.

Concluding Remarks

In 2024, operating expenses increased further to a total of EUR 18.5M, while income grew even more, with non-earmarked income of EUR 8.2M and earmarked income of EUR 10.9M, bringing total income for 2024 to EUR 19.1M. The year 2024 will close with a gross result of EUR 0.52M. Importantly, only 17% of EBMT income was spent on governance, while 83% of resources were allocated to the Society's mission goals. For reference, the overhead ratios of non-profit organisations with an 'A' efficiency rating range from 11% to 20% (CharityWatch.org).

At the time of writing this report, we are awaiting the financial assessment of an independent auditor. We trust that we will obtain an 'unqualified opinion', affirming that EBMT continues to uphold its high standards of management, maintain financial stability, and allocate funds appropriately to its mission, just as in 2023 and previous

years.

In conclusion, with its steady income growth covering its increasing expenses and sufficient reserves to address unexpected circumstances, EBMT remains a financially healthy organisation. To ensure a sustainable balance between income and expenditure, EBMT is developing a consolidation programme.

Financial Highlights 2024

SOURCE OF INCOME	EUR	%	DESTINATION OF RESOURCES	EUR	%
EBMT MEMBERS DONATIONS	€43,000	0.2%	SCIENTIFIC STUDIES	€6,258,000	33.8%
SCIENTIFIC SPONSORS DONATIONS	€549,000	2.9%	EBMT REGISTRY	€2,111,000	11.4%
ANNUAL MEETING	€7,035,000	36.9%	ANNUAL MEETING	€3,587,000	19.3%
RESULTS FROM INVESTMENTS	€588,000	3.1%	EDUCATIONAL ACTIVITIES	€2,021,000	10.9%
			STANDARDS & ACCREDITATION (JACIE)	€1,432,000	7.7%
NON-EARMARKED INCOME	€8,215,000	43.1%	TOTAL MISSION COST	€15,409,000	83.1%
GRANTS FOR STUDIES, CLINICAL TRIALS & EDUCATION	€9,491,000	49.8%	MANAGEMENT AND ADMINISTRATION	€3,138,000	16.9%
ACCREDITATION (JACIE)	€1,359,000	7.1%			
EARMARKED INCOME	€10,850,000	56.9%			

SOURCE OF INCOME	EUR	%	DESTINATION OF RESOURCES	EUR	%
TOTAL INCOME	€19,065,000	100.0%	TOTAL EXPENDITURE	€18,547,000	100.0%

FINANCIAL OUTCOME	EUR	%
TOTAL INCOME	€19,065,000	100.0%
TOTAL COSTS	€18,547,000	97.3%
GROSS RESULTS	€518,000	2.7%
EARMARKED	- €1,303,000	- 6.8%
NET RESULT	€1,821,000	9.5%

At the time of the report release date (March 27, 2025), the audit process is pending completion